The development of immunotherapies called checkpoint inhibitors to treat melanoma has changed the way doctors approach the disease. Jeffrey S. Weber, MD, PhD, deputy director of NYU Langone’s Perlmutter Cancer Center, was at the forefront of this effort and continues to lead clinical trials in an effort to improve treatments for this disease, which is the deadliest form of skin cancer.
Dr. Weber spoke with OncLive On Air about the path that led him to treat people who have cancer and melanoma specifically, his own research to develop immunotherapies for melanoma, and what lies ahead for people with advanced melanoma.
“Looking ahead, I think that we have to do a better job at having biomarkers and picking the patients who would be most likely to benefit from treatment,” says Dr. Weber, who is also co-director of NYU Langone’s Melanoma Research Program.
Listen to Dr. Weber’s entire interview with OncLive On Air.